Stockreport

Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostat...

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com
PDF - Extended follow-up in prostate cancer models demonstrated durable anti-tumor responses with ATNM-400, exceeding those achieved with the androgen receptor pathway inhi [Read more]